SEC Form 4 · accession 0001209191-17-001510
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven L. Krill
Officer — EVP & Chief Scientific Officer
Period of report
Dec 15, 2016
Accepted (ET)
Jan 4, 2017 · 7:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 15, 2016 | M | 3,730 | $4.42 | A | 3,730 | D | |
| Common Stock | Dec 15, 2016 | S | 3,730 | $74.7896 | D | 0 | D | |
| Common Stock | Dec 15, 2016 | M | 6,270 | $12.67 | A | 6,270 | D | |
| Common Stock | Dec 15, 2016 | S | 6,270 | $74.7896 | D | 0 | D | |
| Common Stock | Dec 19, 2016 | M | 2,683 | $12.67 | A | 2,683 | D | |
| Common Stock | Dec 19, 2016 | S | 2,683 | $75.6066 | D | 0 | D | |
| Common Stock | Dec 19, 2016 | M | 7,317 | $12.63 | A | 7,317 | D | |
| Common Stock | Dec 19, 2016 | S | 7,317 | $75.6066 | D | 0 | D | |
| Common Stock | Dec 20, 2016 | M | 10,000 | $12.63 | A | 10,000 | D | |
| Common Stock | Dec 20, 2016 | S | 10,000 | $76.6876 | D | 0 | D | |
| Common Stock | Dec 21, 2016 | M | 2,683 | $12.63 | A | 2,683 | D | |
| Common Stock | Dec 21, 2016 | S | 2,683 | $77.1747 | D | 0 | D | |
| Common Stock | Dec 21, 2016 | M | 7,569 | $46.09 | A | 7,569 | D | |
| Common Stock | Dec 21, 2016 | S | 7,569 | $77.1747 | D | 0 | D | |
| Common Stock | Dec 22, 2016 | M | 5,126 | $46.09 | A | 5,126 | D | |
| Common Stock | Dec 22, 2016 | S | 5,126 | $76.7794 | D | 0 | D | |
| Common Stock | Dec 23, 2016 | M | 5,127 | $46.09 | A | 5,127 | D | |
| Common Stock | Dec 23, 2016 | S | 5,127 | $78.6069 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.42 | Dec 15, 2016 | M | 3,730 | D | — | Apr 18, 2023 | Common Stock | 3,730 | 5,480 | D |
| Stock Option (right to buy)F2 | $12.67 | Dec 15, 2016 | M | 6,270 | D | — | Apr 7, 2024 | Common Stock | 6,270 | 11,635 | D |
| Stock Option (right to buy)F2 | $12.67 | Dec 19, 2016 | M | 2,683 | D | — | Apr 7, 2024 | Common Stock | 2,683 | 8,952 | D |
| Stock Option (right to buy)F3 | $12.63 | Dec 19, 2016 | M | 7,317 | D | — | Aug 25, 2024 | Common Stock | 7,317 | 32,683 | D |
| Stock Option (right to buy)F3 | $12.63 | Dec 20, 2016 | M | 10,000 | D | — | Aug 25, 2024 | Common Stock | 10,000 | 22,683 | D |
| Stock Option (right to buy)F3 | $12.63 | Dec 21, 2016 | M | 2,683 | D | — | Aug 25, 2024 | Common Stock | 2,683 | 20,000 | D |
| Stock Option (right to buy)F4 | $46.09 | Dec 21, 2016 | M | 7,569 | D | — | Mar 12, 2025 | Common Stock | 7,569 | 63,717 | D |
| Stock Option (right to buy)F4 | $46.09 | Dec 22, 2016 | M | 5,126 | D | — | Mar 12, 2025 | Common Stock | 5,126 | 58,591 | D |
| Stock Option (right to buy)F4 | $46.09 | Dec 23, 2016 | M | 5,127 | D | — | Mar 12, 2025 | Common Stock | 5,127 | 53,464 | D |
Explanation of responses
- F125% of the shares subject to the option vested on April 19, 2014 and the remainder shall vest in equal monthly installments over a period of three years.
- F225% of the shares subject to the option vested on April 8, 2015 and the remainder shall vest in equal monthly installments over a period of three years.
- F325% of the shares subject to the option vested on August 26, 2015 and the remainder shall vest in equal monthly installments over a period of three years.
- F425% of the shares subject to the option vested on March 13, 2016 and the remainder shall vest in equal monthly installments over a period of three years.